Anlong Bio Appoints Mr. Gao Jie as Vice President of Oligonucleotide Therapeutics

Mr. Gao Jie graduated early from Peking Union Medical College and has more than ten years of experience in biopharmaceutical R&D, with experience in the development of nearly a hundred preclinical pharmacology projects. He is highly experienced in patent analysis, product design, screening, animal models, and pharmacological toxicological analysis of small nucleic acid drugs. Mr. Gao Jie is the founder of Anlong's small nucleic acid department, where he established the early R&D of small nucleic acids at Anlong, including vector construction, chemical modification, and project team management. He led his team to sign and successfully complete project collaborations between Anlong and companies such as KaronTech and Salubris. Before joining Anlong, Mr. Gao Jie served as a project manager and BD manager at Beijing Borui Shian Technology Co., Ltd., participating in multiple preclinical pharmacology, toxicology, and animal model studies for various drugs. Mr. Gao Jie also worked at Beijing Zhengdan International Technology Co., Ltd., where he initially served as the head of gene therapy product development, engaging in the establishment and preparation of AAV vectors.

Dr. Zhao Chunlin, Founder, Chairman and CEO of AnlongMr. Gao Jie is highly sensitive to market information in the biopharmaceutical field and excels at seizing opportunities. He took the lead in establishing Anlong's small nucleic acid team. From liver-targeted small nucleic acid products, the focus has now expanded to extrahepatic targeted delivery, with rapid progress. In response to market demand, Anlong's small nucleic acid team actively sought external cooperation from its inception, completing the development of HBV products with Kanger Technology and hypertension products with Salubris. We thank Mr. Gao Jie for his dedication and commitment, and we hope that he continues to excel in his new role, achieving even greater success.

Mr. Gao Jie"I am grateful for the company’s support and encouragement. As part of Anlong's team, I have had the privilege to collaborate with and witness the company’s rapid growth alongside outstanding colleagues. Anlong boasts a highly professional R&D team with significant expertise. I am very excited to continue advancing the development of small nucleic acid projects in my new role, further accelerating Anlong's growth."

About Anlong

Anlong was founded in August 2019 by Dr. Zhao Chunlin, a seasoned expert in the field, leveraging groundbreaking advances in molecular biology to develop gene-based drugs, including new drug research utilizing technologies such as gene regulation, gene therapy, and gene editing. Anlong focuses on areas with significant market potential, developing innovative gene drugs with proprietary intellectual property rights, most of which rank among the leading positions in China and internationally. Anlong is committed to becoming a leader in China’s gene drug industry, creating affordable innovative medicines for patients.

Source of the article:Anlong